Stake logo

RGEN

Repligen Corp

About RGEN

Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins. The Filtration products are used in process development and process scale production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all monoclonal antibody (mAb) based drugs on the market.

Buy US stocks in Australia starting with RGEN. Open an account and start investing today!

Market Capitalisation

$10.71B

Price-earnings ratio

-

Dividend yield

0.00%

Volume

0

High today

$198.12

Low today

$189.03

Open price

$0.00

52-week high

$262.26

52-week low

$137.21


RGEN FAQs

One share of Repligen Corp is valued at $192.45.

The ticker symbol for Repligen Corp is RGEN.

To buy RGEN stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake Wall St
  3. Deposit directly into your Stake wallet and you're ready to invest in RGEN

As of 07/02/2023 Repligen Corp has a market cap of $11B.

The Repligen Corp 52-week high stock price is $262.26.

The Repligen Corp 52-week low stock price is $137.21.


Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.